Peptide libraries with non-canonical amino acids

    公开(公告)号:US11919972B2

    公开(公告)日:2024-03-05

    申请号:US16673657

    申请日:2019-11-04

    Inventor: Anders Eliasen

    Abstract: Disclosed are peptides having non-canonical amino acids. These peptides are useful, for example, as protein binding agents. Libraries of such peptides can be used, for example to screen and select protein binding agents. The broader chemical space of the disclosed peptides can provide peptide with different, improved, more specific, and/or pharmaceutically compatible peptides and protein binding agents. In some forms, the peptides can have the following structure (I):




    including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1 Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.

    METHODS AND KITS FOR SEPARATING NUCLEIC ACIDS BY SIZE

    公开(公告)号:US20170268047A1

    公开(公告)日:2017-09-21

    申请号:US15460489

    申请日:2017-03-16

    Inventor: Yousef Haj-Ahmad

    Abstract: Disclosed are methods and kits for isolating nucleic acids having a size above a desired cut-off size from a nucleic acid containing sample. The method comprises combining the sample with a binding buffer, alcohol and silicon carbide to provide a binding mixture. Nucleic acids having a size above the desired cut-off size are selectively bound to the silicon carbide. The cut-off size for selective binding to the silicon carbide is determined by the alcohol concentration of the binding mixture. The bound nucleic acids are separated from the remaining sample. The bound nucleic acids are optionally washed and then eluted from the silicon carbide. The kit comprises a buffer binding to be diluted with alcohol to provide an alcohol concentration of about 1 to about 50% (v/v), a wash solution, an elution solution, silicon carbide and instructions for adjusting the alcohol concentration to selectively bind nucleic acids having a size above the desired cut-off size.

    METHODS OF SYNTHESIZING POLYNUCLEOTIDES
    6.
    发明申请

    公开(公告)号:US20170267998A1

    公开(公告)日:2017-09-21

    申请号:US15532452

    申请日:2015-12-03

    Applicant: AxioMx, Inc.

    Inventor: Michael WEINER

    CPC classification number: C12N15/1072 C12N15/1031 C40B50/14 C12Q2563/179

    Abstract: The present invention is directed to compositions and methods for producing one or more polynucleotides from smaller oligonucleotide segments within an emulsion. In methods of the present invention, a support having one or more capture oligo-nucleotides is contacted with two or more corresponding tile oligonucleotides. Upon hybridization of the tile oligonucleotides to the capture oligonucleotides, a capture complex is formed. This capture complex is emulsified, optionally with reaction reagents or other additives. The emulsion is then incubated at a temperature regimen sufficient for an adjoining extension reaction to occur, such that a polynucleotide may be formed from the tile oligonucleotides that hybridized to a particular support. A particular advantage of this method is that many different polynucleotides may be produced in parallel with surprising efficiency.

    COMPOSITIONS AND METHODS FOR REPRESENTATIONAL SELECTION OF NUCLEIC ACIDS FROM COMPLEX MIXTURE

    公开(公告)号:US20170175109A1

    公开(公告)日:2017-06-22

    申请号:US15451035

    申请日:2017-03-06

    Applicant: Illumina, Inc.

    CPC classification number: C12N15/1072 C12Q1/6837 C12Q2565/515

    Abstract: The invention provides a method of selecting a representational sample of nucleic acid sequences from a complex mixture. The method includes: (a) contacting a complex mixture of nucleic acids under conditions sufficient for hybridization with a population of capture probes complementary to one or more nucleic acids comprising a predetermined portion of the sequence collectively present in the complex mixture to form hybridization complexes of the one or more nucleic acids with the population of probes, the population of capture probes being attached to a solid support, and (b) removing unhybridized nucleic acids to select a representational sample of nucleic acids having a complexity of less than 10% but more than 0.001% of the complex mixture, wherein the representational sample comprises a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of the sequences in the predetermined portion of one or more nucleic acids within the complex mixture. A method of selecting a representational sample of genomic sequences from a complete genome also is provided. The invention further provides a nucleic acid population that includes a representational sample having a complexity of less than 10% but more than 0.001% of a complex mixture, the representational sample comprising a nucleic acid copy having a proportion of each sequence in the copy relative to all other sequences in the copy substantially the same as the proportions of sequences in a predetermined portion of a sequence collectively present in one or more nucleic acids within the complex mixture.

    SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION

    公开(公告)号:US20160333417A1

    公开(公告)日:2016-11-17

    申请号:US15071656

    申请日:2016-03-16

    Inventor: AmirAli Talasaz

    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.

Patent Agency Ranking